Hot Trend Research Tool

Related EBay Products

Yahoo Answers - Resolved Questions

Forum Search - Exact Match

1. "Early Works Poll/ Choose your Favorite - NESP Forum / Taylor Hicks / The Right Place: Latest News and Discussion / "Early ... facet biotech. stephanie birkitt. obama fishing ban. randy kwasniewski ...
2. $FACT Facet Biotech's Board of Directors Rejects Biogen ... - $FACT Facet Biotech's Board of Directors Rejects Biogen Idec's Unsolicited Proposal a StockTwits - recommended traders trading (RSS feeds)
3. AAA Interview (Yes, you read that right) - NESP Forum / Taylor Hicks / The Right Place: Latest News and Discussion / AAA Interview ... facet biotech. stephanie birkitt. obama fishing ban. randy kwasniewski. sequent energy ...
4. Abbott completes acquisition of Facet Biotech - منتدى رابطه مسك - Abbott completes acquisition of Facet Biotech أخبــ Newsــــــار
5. Facet Biotech Reports Third Quarter 2009 Financial Results ... - Facet Biotech Reports Third Quarter 2009 Financial Results أخبــ Newsــــــار
6. TRBN - Trubion Pharmaceuticals Inc. - HotStockMarket Message ... - Facet Biotech is a biotechnology company dedicated to advancing its pipeline of ... Facet Biotech Corporation launched in December 2008 as a spin-off from PDL ...
7. Titoli con farmaco in approvazione 3 - Pagina 20 - Forum di ... - Titoli con farmaco in approvazione 3 Wall Street ... to purchase all of the outstanding shares of common stock of Facet Biotech. Aoxing Pharmaceutical Company Inc. ...
8. Titoli con farmaco in approvazione 3 - Pagina 7 - Forum di ... - Pagina 7- Titoli con farmaco in approvazione 3 Wall Street ... to purchase all of the outstanding shares of Facet Biotech Corporation (NASDAQ: FACT) to $17.50 per share ...
9. Zantrio.com Stock Picks for September 8, 2009 - Alpari (UK)'s ... - Zantrio.com Stock Picks for September 8, 2009 Forex and CFDs: Trade Recommendations ... Facet Biotech was offered $356 mil or $14.50 a share from Biogen after criticizing its ...
10. 美股瞭望 - 第9頁 - 香港人的討論區 Forums.idv.hk 討論香港 - ,,美股瞭望 美國股市 ... 並購交易主題上週五進一步得到鞏固,制藥公司Biogen Idec宣佈向小型公司Facet Biotech發出3.56億美元的收購提議。 領漲個股包括:通用電氣漲42美分,至13.87美元,漲幅3.1%;卡特彼勒漲1.07美元,至46.11美元,漲幅2.4 ...

Blog Search - Exact Match

1. Facet Biotech Has $722M That Says It Pays to Stand Up to Bullies ... - Little Facet Biotech (FACT) had to put up with some awfully patronizing statements from Biogen Idec (BIIB) when the big biotech was waging a $438 mill.
2. Abbott Completes Acquisition of Facet Biotech - ABBOTT PARK, Illinois, April 21, 2010 - Abbott (NYSE: ABT) has completed its acquisition of Facet Biotech.
3. Abbott Completes Acquisition of Facet Biotech: April 21, 2010 - The final step in the acquisition process was a short-form merger of Amber Acquisition Inc., a wholly-owned subsidiary of Abbott, with and into Facet Biotech Corporation. As a result of the merger, all outstanding shares of Facet common ...
4. Abbott Laboratories to Buy Facet Biotech for $722 Million - News ... - Under the terms of the agreement, Abbott will promptly commence a tender offer to purchase all outstanding shares of Facet Biotech at $27 per share. The closing of the tender offer is conditioned on the tender of a majority of the ...
5. Abbott Reports Strong Second Quarter Results; Confirms Double ... - ... Confirms Double-Digit Ongoing … PR Newswire UK (press release) Completed Acquisition of Facet Biotech; Advanced MS Compound into Phase III: Completed the acquisition of Facet Biotech Corporation, strengthening Abbott's … and more » ...
6. Abbott buys Facet Biotech for $450M - FierceBiotech - Abbott has succeeded where Biogen Idec once failed. The company announced late Tuesday that it's purchasing Facet Biotech for $450 million, or $27 a share. That's 67 percent premium over the... Read more...
7. Abbott to Buy Facet Biotech for 67% Premium - DealBook Blog ... - Abbott Laboratories announced late Tuesday that it had agreed to buy Facet Biotech for a net price of $450 million in cash, in a move aimed at expanding its drug pipeline, including for treatments for multiple sclerosis.
8. Biogen Idec shares rise on market speculation over potential ... - December 15th, 2009 Biogen threatens proxy fight in Facet bidNEW YORK — Biotechnology company Biogen Idec Inc. threatened a proxy fight Tuesday to remove a majority of Facet Biotech Corp.'s directors, heating up an already volatile ...
9. Stocks in the News: Facet Biotech, InterMune, American Eagle ... - The following is a round-up of news likely to affect stock prices today: Facet Biotech (FACT) shares soared over 67% in premarket trading after it agreed to be acquired by Abbott Laboratories (ABT) for $722 million, or $27 a share.
10. The Facet Biotech Buyout Saga (FACT, BIIB, ABT, PDLI) : BioHealth ... - Facet Biotech Corporation (NASDAQ: FACT) is a buyout saga that seemed as though it would never end in 2009. The company is now finally being acquired, but not by Biogen Idec (NASDAQ: BIIB). Abbott Laboratories (NYSE: ABT) announced last ...

News Search

1. Abbott Labs Surpasses by a Penny - Zacks.com -

   RTT News

   Abbott Labs Surpasses by a Penny Zacks.com Meanwhile, the recent acquisition of Facet Biotech has helped strengthen Abbott Labs' early- and mid-stage oncology portfolio. Abbott Labs is also working ... Abbott sales climb, plots further growth in emerging marketsPharma Times all 368 news articles »

2. Abbott Reports Strong Second Quarter Results; Confirms Double-Digit Ongoing ... - MarketWatch (press release) -

   Abbott Reports Strong Second Quarter Results; Confirms Double-Digit Ongoing ... MarketWatch (press release) Completed Acquisition of Facet Biotech; Advanced MS Compound into Phase III: Completed the acquisition of Facet Biotech Corporation, strengthening Abbott's ... and more »

YouTube Search - Exact Match

1. News Update: Facet Biotech Corp. (NASDAQ:FACT) Skyrockets on Acquisition by Abbott Labs -

   	News Update: Facet Biotech Corp. (NASDAQ:FACT) Skyrockets on Acquisition by Abbott Labs 3/10/2010-Shares of Facet Biotech Corp. (NASDAQ:FACT) are trading 66.2% higher to $26.94 Wednesday after Abbott Laboratories (NYSE:ABT) agreed to buy the biotechnology company for $27 a share, for a net transaction value of about $450 million, enhancing Abbott's early and mid stage pharmaceutical pipeline. The transaction is expected to close in the second quarter of 2010.	From: TradeTheTrend Views: 35 0 ratings
   	Time: 00:45	More in News & Politics

2. Fly on the Wall Market Snapshot: March 10, 2010 -

   	Fly on the Wall Market Snapshot: March 10, 2010 Good Morning. It's Wednesday, March 10, 2010. At this hour, US equity futures are higher. Overseas, the Asian markets were mixed, while the European markets are mostly higher. Today's UPGRADES include: InterMune (ITMN) upgraded to Outperform from Market Perform at Wells Fargo. Analog Devices (ADI) upgraded to Outperform from Market Perform at Bernstein. Global Payments (GPN) upgraded to Positive from Neutral at Susquehanna. DOWNGRADES: J.Crew (JCG) downgraded to Hold from Buy at Citigroup.. Vale SA (VALE) downgraded to Neutral from Buy at UBS. FPIC Insurance (FPIC) downgraded to Perform from Outperform at Oppenheimer. Hot News: Abbott Labs (ABT) acquired Facet Biotech (FACT) for $27 per share, or approximately $450M, to enhance Abbott's early and mid-stage pharmaceutical pipeline. InterMune (ITMN) announced that the FDAs Pulmonary-Allergy Drugs Advisory Committee voted 9-3 to recommend approval of Esbriet for the treatment of patients with idiopathic pulmonary fibrosis to reduce decline in lung function. EA SPORTS, a label of Electronic Arts (ERTS), announced that EA SPORTS Active 2.0 is now in development and will be available this fall on PlayStation3 (SNE), Wii (NTDOY), the iPhone (AAPL) and the iPod touch. Acacia Research Corp. (ACTG) announced that a subsidiary has acquired rights to 48 US patents, 72 foreign counterparts, and associated applications from a leading international research institute. The patents cover various wireless and other communications <b>...</b>	From: TradeTheTrend Views: 58 0 ratings
   	Time: 02:01	More in News & Politics

3. September 4 Biz Minute -

   	September 4 Biz Minute H&R Block's fiscal first-quarter loss widened slightly, as costs from a takeover more than offset other expense cuts and an unusual profit in business services. Biogen Idec said today it had offered to acquire Facet Biotech, a partner in developing multiple sclerosis and cancer drugs, in a deal valued at about $355 million. CIT Group said it has extended the contract of Chief Executive Jeffrey Peek for one year, even though his decisions to expand into risky businesses helped to push the lender to the brink of bankruptcy. Toshiba plans to bid for French nuclear group Areva's power transmission and distribution unit in a deal that could top $5 billion. Google announced that its China president, Kai-Fu Lee, is leaving the company to work on his own venture. Lee was the center of a legal fight when he left Microsoft in 2005 to join Google. The G20 will promise this weekend to keep economic support packages in place until recovery is certain and seek to reassure financial markets they have credible plans to withdraw the stimulus when appropriate.	From: inlandbizpress Views: 42 1 ratings
   	Time: 01:27	More in News & Politics

4. MorningMarket Update: March 10, 2010 -

   	MorningMarket Update: March 10, 2010 March 10, 2010: 8:15 AM ET --- US stock futures are trading higher Wednesday as investors await M&A news and wholesale inventory data. Wholesale inventories for January are due for release today. In corporate news, Facet Biotech (NASDAQ:FACT) may be in the spotlight on news that Abbott Laboratories is purchasing the company for $722 million. The Children's Place Retail Stores (NASDAQ:PLCE) reported fiscal Q4 EPS of $1.03, ex-items, inline withconsensus estimates. Revenues for the quarter rose 5% year-over-year to $462.8 million, inline with the consensus estimates. The Dow Jones Industrial Average (DJI) futures are trading 6.00 points above fair value, the S&P500 (INX) futures are trading 0.60 points above fair value, and the Nasdaq Composite (IXIC) futures are trading 3.25 points above fair value.	From: TradeTheTrend Views: 9 0 ratings
   	Time: 01:14	More in News & Politics

Forum Search - Broad Match

1. $FACT Facet Biotech's Board of Directors Rejects Biogen ... - $FACT Facet Biotech's Board of Directors Rejects Biogen Idec's Unsolicited Proposal a StockTwits - recommended traders trading (RSS feeds)
2. Archus Orthopedics designing post-ADR facet device ... - Archus Orthopedics designing post-ADR facet device Arthroplasty Central ... and 2) to do the same "naturally" w/biotech. It'll be interesting to see which is the ...
3. Best US CNC Mill for the money - CNCzone.com-The Largest ... - Best US CNC Mill for the money General Metal Working Machines ... steppers (I'm a mechanical engineer for a biotech instrumentation company, and we make instruments over $200k ...
4. Myth of the biomedical bubble - CareCure Forums - Myth of the biomedical bubble Health & Science News ... is to combine size with nifty leadership, a mix which few pharmaceutical or biotech firms have currently. ...
5. Peer-To-Peer News - The Week In Review - September 2nd, '06 ... - Peer-To-Peer News - The Week In Review - September 2nd, '06 Peer to Peer
6. Spinal Elements, Inc. Receives FDA 510(k) Market Clearance ... - Spinal Elements, Inc. Receives FDA 510(k) Market Clearance for its Lucent(R) Emerging Surgical & Medical Technology
7. TRBN - Trubion Pharmaceuticals Inc. - HotStockMarket Message ... - TRBN - Trubion Pharmaceuticals Inc. Penny Stocks ... About Facet Biotech. Facet Biotech is a biotechnology company dedicated to advancing its pipeline of four ...
8. Titoli con farmaco in approvazione 3 - Pagina 20 - Forum di ... - Titoli con farmaco in approvazione 3 Wall Street ... to purchase all of the outstanding shares of common stock of Facet Biotech. Aoxing Pharmaceutical Company Inc. ...
9. Titoli con farmaco in approvazione 3 - Pagina 7 - Forum di ... - Pagina 7- Titoli con farmaco in approvazione 3 Wall Street ... to purchase all of the outstanding shares of Facet Biotech Corporation (NASDAQ: FACT) to $17.50 per share ...
10. Zantrio.com Stock Picks for September 8, 2009 - Alpari (UK)'s ... - Zantrio.com Stock Picks for September 8, 2009 Forex and CFDs: Trade Recommendations ... Facet Biotech was offered $356 mil or $14.50 a share from Biogen after criticizing its ...

Blog Search - Broad Match

1. Facet Biotech Acquired By Abbott - CALIFORNIA (GaeaTimes.com)- In a move that may have an impact on the future of biotechnology and medical research, Abbott Laboratories is going to acquire noted biotechnology products developer Facet Biotech Corp.
2. Facet Biotech Has $722M That Says It Pays to Stand Up to Bullies ... - Little Facet Biotech (FACT) had to put up with some awfully patronizing statements from Biogen Idec (BIIB) when the big biotech was waging a $438 mill.
3. Abbott Completes Acquisition of Facet Biotech - ABBOTT PARK, Illinois, April 21, 2010 - Abbott (NYSE: ABT) has completed its acquisition of Facet Biotech.
4. Abbott Completes Acquisition of Facet Biotech: April 21, 2010 - The final step in the acquisition process was a short-form merger of Amber Acquisition Inc., a wholly-owned subsidiary of Abbott, with and into Facet Biotech Corporation. As a result of the merger, all outstanding shares of Facet common ...
5. Abbott Laboratories to Buy Facet Biotech for $722 Million - News ... - Under the terms of the agreement, Abbott will promptly commence a tender offer to purchase all outstanding shares of Facet Biotech at $27 per share. The closing of the tender offer is conditioned on the tender of a majority of the ...
6. Abbott buys Facet Biotech for $450M - FierceBiotech - Abbott has succeeded where Biogen Idec once failed. The company announced late Tuesday that it's purchasing Facet Biotech for $450 million, or $27 a share. That's 67 percent premium over the... Read more...
7. Abbott to Buy Facet Biotech for 67% Premium - DealBook Blog ... - Abbott Laboratories announced late Tuesday that it had agreed to buy Facet Biotech for a net price of $450 million in cash, in a move aimed at expanding its drug pipeline, including for treatments for multiple sclerosis.
8. Biogen Idec shares rise on market speculation over potential ... - December 15th, 2009 Biogen threatens proxy fight in Facet bidNEW YORK — Biotechnology company Biogen Idec Inc. threatened a proxy fight Tuesday to remove a majority of Facet Biotech Corp.'s directors, heating up an already volatile ...
9. Stocks in the News: Facet Biotech, InterMune, American Eagle ... - The following is a round-up of news likely to affect stock prices today: Facet Biotech (FACT) shares soared over 67% in premarket trading after it agreed to be acquired by Abbott Laboratories (ABT) for $722 million, or $27 a share.
10. The Facet Biotech Buyout Saga (FACT, BIIB, ABT, PDLI) : BioHealth ... - Facet Biotech Corporation (NASDAQ: FACT) is a buyout saga that seemed as though it would never end in 2009. The company is now finally being acquired, but not by Biogen Idec (NASDAQ: BIIB). Abbott Laboratories (NYSE: ABT) announced last ...

YouTube Search - Broad Match

1. News Update: Facet Biotech Corp. (NASDAQ:FACT) Skyrockets on Acquisition by Abbott Labs -

   	News Update: Facet Biotech Corp. (NASDAQ:FACT) Skyrockets on Acquisition by Abbott Labs 3/10/2010-Shares of Facet Biotech Corp. (NASDAQ:FACT) are trading 66.2% higher to $26.94 Wednesday after Abbott Laboratories (NYSE:ABT) agreed to buy the biotechnology company for $27 a share, for a net transaction value of about $450 million, enhancing Abbott's early and mid stage pharmaceutical pipeline. The transaction is expected to close in the second quarter of 2010.	From: TradeTheTrend Views: 35 0 ratings
   	Time: 00:45	More in News & Politics

2. Fly on the Wall Market Snapshot: March 10, 2010 -

   	Fly on the Wall Market Snapshot: March 10, 2010 Good Morning. It's Wednesday, March 10, 2010. At this hour, US equity futures are higher. Overseas, the Asian markets were mixed, while the European markets are mostly higher. Today's UPGRADES include: InterMune (ITMN) upgraded to Outperform from Market Perform at Wells Fargo. Analog Devices (ADI) upgraded to Outperform from Market Perform at Bernstein. Global Payments (GPN) upgraded to Positive from Neutral at Susquehanna. DOWNGRADES: J.Crew (JCG) downgraded to Hold from Buy at Citigroup.. Vale SA (VALE) downgraded to Neutral from Buy at UBS. FPIC Insurance (FPIC) downgraded to Perform from Outperform at Oppenheimer. Hot News: Abbott Labs (ABT) acquired Facet Biotech (FACT) for $27 per share, or approximately $450M, to enhance Abbott's early and mid-stage pharmaceutical pipeline. InterMune (ITMN) announced that the FDAs Pulmonary-Allergy Drugs Advisory Committee voted 9-3 to recommend approval of Esbriet for the treatment of patients with idiopathic pulmonary fibrosis to reduce decline in lung function. EA SPORTS, a label of Electronic Arts (ERTS), announced that EA SPORTS Active 2.0 is now in development and will be available this fall on PlayStation3 (SNE), Wii (NTDOY), the iPhone (AAPL) and the iPod touch. Acacia Research Corp. (ACTG) announced that a subsidiary has acquired rights to 48 US patents, 72 foreign counterparts, and associated applications from a leading international research institute. The patents cover various wireless and other communications <b>...</b>	From: TradeTheTrend Views: 58 0 ratings
   	Time: 02:01	More in News & Politics

3. September 4 Biz Minute -

   	September 4 Biz Minute H&R Block's fiscal first-quarter loss widened slightly, as costs from a takeover more than offset other expense cuts and an unusual profit in business services. Biogen Idec said today it had offered to acquire Facet Biotech, a partner in developing multiple sclerosis and cancer drugs, in a deal valued at about $355 million. CIT Group said it has extended the contract of Chief Executive Jeffrey Peek for one year, even though his decisions to expand into risky businesses helped to push the lender to the brink of bankruptcy. Toshiba plans to bid for French nuclear group Areva's power transmission and distribution unit in a deal that could top $5 billion. Google announced that its China president, Kai-Fu Lee, is leaving the company to work on his own venture. Lee was the center of a legal fight when he left Microsoft in 2005 to join Google. The G20 will promise this weekend to keep economic support packages in place until recovery is certain and seek to reassure financial markets they have credible plans to withdraw the stimulus when appropriate.	From: inlandbizpress Views: 42 1 ratings
   	Time: 01:27	More in News & Politics

4. Nanotechnology: "Big Things, Small Packages" -

   	Nanotechnology: "Big Things, Small Packages" Nanotechnology research has been building up for some time, and is on the brink of revolutionizing industries from personal computing all the way up to cancer treatment. In this video, CEO of Plunkett Research, Ltd.™, Jack W. Plunkett,, recaps the history of Nanotechnology, discusses the areas of the world contributing most to the research and development, and illustrates examples of both the current uses of nanotechnology and the future impacts this industry is going to have on every facet of our lives. As always, visit us at: www.facebook.com twitter.com and at www.plunkettresearch.com	From: plunkettresearch Views: 289 0 ratings
   	Time: 06:42	More in Science & Technology

5. MorningMarket Update: March 10, 2010 -

   	MorningMarket Update: March 10, 2010 March 10, 2010: 8:15 AM ET --- US stock futures are trading higher Wednesday as investors await M&A news and wholesale inventory data. Wholesale inventories for January are due for release today. In corporate news, Facet Biotech (NASDAQ:FACT) may be in the spotlight on news that Abbott Laboratories is purchasing the company for $722 million. The Children's Place Retail Stores (NASDAQ:PLCE) reported fiscal Q4 EPS of $1.03, ex-items, inline withconsensus estimates. Revenues for the quarter rose 5% year-over-year to $462.8 million, inline with the consensus estimates. The Dow Jones Industrial Average (DJI) futures are trading 6.00 points above fair value, the S&P500 (INX) futures are trading 0.60 points above fair value, and the Nasdaq Composite (IXIC) futures are trading 3.25 points above fair value.	From: TradeTheTrend Views: 9 0 ratings
   	Time: 01:14	More in News & Politics

Image Search

1. 376204 123982823665777 ValueHuntr png
2. 495105 facet pos jpg
3. bar phase2 jpg
4. bar preclinical jpg
5. charts dll 2 1 17 0 0 008001830 03NA000000FACT WD=484 HT=220 FS=80 FTS AM34=0|AI34=0
6. Facet Biotech Chart via Yahoo - current price of $6 56 the only downside appears to be from further institutional selling Looking at the chart and volume it appears most of the selling was completed by the end of January On Jan 7 Facet announced they had restructured the company and cash burn for 2009 would be $110M In this presentation Facet maintains they can fund business operations for four years
7. PDLI rev1 JPG - 2008 company spun off its R D organization to Facet Biotech Corporation Currently PDL continues to generate royalties through licensing agreements based on its humanized antibody technology In 2007 revenues amounted to $259 million a 4 0 increase from 2006 6 Revenue growth has been slowing down over the past few years The revenue growth rate was 57 2 65 0 and 44 0 in
8. fact termination1 png w=450 h=531 - board at the annual meeting five officers will receive around $10M in termination payments Not bad for a few quarters work Those payments are pretty obscene so we ve set them out below If the company sustains another twelve months of cash burn and must pay out all its contractual obligations it has next to no value in liquidation aside from the intellectual property
9. graphic news jpg - We are committed to keeping investors apprised on our strategy vision and business operations in a timely manner
10. saupload epv2 jpg - PDL s PDLI generous margins stem from its decision to hive off its riskier drug development business into a separate company Facet Biotech FACT leaving it as a thinly staffed listed

Google Insight - Related and Rising Searches

Yahoo Answers - Open Questions

Related Keyword Suggestions

(Hit Submit to see the list of suggested Keywords.)

Enter Keyword (Theme)